Fireside Chat, Panel, Conference Presentation
Rewriting the Rules: Scaling Innovation for Rare Diseases | Global Conference 2026
Milken InstituteBecky Quick, Nicola Blackwood, David Fajgenbaum, Michael Hund, Neil Kumar, William H. Lewis
- Drug Repurposing and Patent Incentives: Speakers predict that extending patent life by five to 20 years for generic drugs could make 200 to 800 additional treatments immediately available, addressing a market where 80% of approved drugs are already generic but lack financial incentives for further development; this is expected to unlock "hundreds" of patients for conditions like Rosdorfman and Bachman-Bopp syndrome by leveraging safe, existing compounds.
- Operational Expansion and AI Integration: Non-profit pipelines are projected to grow from 10 to 25 active programs with thousands more in the queue, while AI models are anticipated to scan drug-disease permutations at a volume of approximately 1,000 ideas monthly to identify "low-hanging fruit" and accelerate the identification of monogenic rare diseases.
- Regulatory and Diagnostic Shifts: The industry expects a transition to "adaptive trials," "decentralized hub-and-spoke models," and a restructured regulatory consultative process involving the MHRA and FDA to enable faster approvals; simultaneous advancements in newborn sequencing (targeting 100,000 patients) aim to facilitate diagnosis within the first 24 months to prevent lifetime disability.
- Economic Models and Market Dynamics: With the US rare disease economic burden exceeding $1 trillion annually and the global market approaching $300 billion, speakers anticipate a need for new reimbursement structures (such as delinked models) and "first or best in class" strategies, noting that European pricing pressures could cede market dominance to China unless "exemptions" or "hard conversations" regarding profit pools occur.
- Collaborative Frameworks and Capital: Future development is expected to rely on "umbrella trials" (leveraging Stanford/CRISPR collaborations to bypass 5-7 year timelines), "venture philanthropy" with upstream royalty agreements, and patient advocacy groups directing drug development, all supported by data platforms that may eventually enable "digital twins" for real-time patient monitoring.